Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review

Trana Hussaini1,2 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada Abstract: The treatment for chronic hepatitis C has been revolutionized with the development of direct-acting ant...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Hussaini T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Hepatitis C Paritaprevir Ombitasvir Dasabuvir 3D Regimen Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/5db086ab4bc344cea8a7abd9d0ae81d0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5db086ab4bc344cea8a7abd9d0ae81d0
record_format	dspace
spelling	oai:doaj.org-article:5db086ab4bc344cea8a7abd9d0ae81d02021-12-02T06:15:58ZParitaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review1179-1535https://doaj.org/article/5db086ab4bc344cea8a7abd9d0ae81d02016-05-01T00:00:00Zhttps://www.dovepress.com/paritaprevirritonavir-ombitasvir-and-dasabuvir-the-3d-regimen-for-the--peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Trana Hussaini1,2 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada Abstract: The treatment for chronic hepatitis C has been revolutionized with the development of direct-acting antiviral agents. Several regimens have been approved and are currently used in clinical practice, treating a wide range of patient populations infected with hepatitis C. The interferon-free combination of paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD or the three-drug [3D] regimen) with or without ribavirin is indicated for the treatment of chronic hepatitis C in both treatment-naïve and experienced patients infected with genotype 1, including those coinfected with HIV and patients post-liver transplantation. More recently, paritaprevir/ritonavir-ombitasvir (PrO, or 2D regimen) has been approved in hepatitis C virus patients infected with genotype 4. This review will summarize pharmacokinetic and clinical efficacy data for the 3D regimen in an attempt to help the clinicians delineate its place in the ever-increasing direct-acting antiviral armamentarium for the treatment of chronic hepatitis C. Keywords: hepatitis C, paritaprevir, ombitasvir, dasabuvir, 3D regimenHussaini TDove Medical PressarticleHepatitis CParitaprevirOmbitasvirDasabuvir3D RegimenDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol 2016, Iss Issue 1, Pp 61-68 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Hepatitis C Paritaprevir Ombitasvir Dasabuvir 3D Regimen Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Hepatitis C Paritaprevir Ombitasvir Dasabuvir 3D Regimen Diseases of the digestive system. Gastroenterology RC799-869 Hussaini T Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
description	Trana Hussaini1,2 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada Abstract: The treatment for chronic hepatitis C has been revolutionized with the development of direct-acting antiviral agents. Several regimens have been approved and are currently used in clinical practice, treating a wide range of patient populations infected with hepatitis C. The interferon-free combination of paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD or the three-drug [3D] regimen) with or without ribavirin is indicated for the treatment of chronic hepatitis C in both treatment-naïve and experienced patients infected with genotype 1, including those coinfected with HIV and patients post-liver transplantation. More recently, paritaprevir/ritonavir-ombitasvir (PrO, or 2D regimen) has been approved in hepatitis C virus patients infected with genotype 4. This review will summarize pharmacokinetic and clinical efficacy data for the 3D regimen in an attempt to help the clinicians delineate its place in the ever-increasing direct-acting antiviral armamentarium for the treatment of chronic hepatitis C. Keywords: hepatitis C, paritaprevir, ombitasvir, dasabuvir, 3D regimen
format	article
author	Hussaini T
author_facet	Hussaini T
author_sort	Hussaini T
title	Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
title_short	Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
title_full	Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
title_fullStr	Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
title_full_unstemmed	Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review
title_sort	paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3d regimen for the treatment of chronic hepatitis c virus infection: a concise review
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/5db086ab4bc344cea8a7abd9d0ae81d0
work_keys_str_mv	AT hussainit paritaprevirritonavirombitasviranddasabuvirthe3dregimenforthetreatmentofchronichepatitiscvirusinfectionaconcisereview
_version_	1718399991558438912

Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review

Ejemplares similares